Anticancer Bioscience
Dedicated to the development of synthetic lethal therapies that address unmet medical needs.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
$10.6m Valuation: $55.0m | Seed | ||
| Total Funding | 000k | ||
Related Content
Anticancer Bioscience is an international precision oncology company focused on developing targeted cancer therapies through synthetic lethal approaches. The company leverages discoveries from the J. Michael Bishop Institute of Cancer Research to identify novel compounds that target genetic and epigenetic vulnerabilities in cancer cells. Anticancer Bioscience operates in the biotechnology and pharmaceutical markets, serving healthcare providers, research institutions, and pharmaceutical companies. The business model revolves around translating basic research breakthroughs into clinical assets, which are then commercialized. Revenue is generated through the development and licensing of proprietary cancer therapeutics and drug delivery technologies. The company benefits from exclusive pipeline agreements and patents transferred from the J. Michael Bishop Institute, ensuring a steady flow of innovative cancer treatment solutions.
Keywords: precision oncology, synthetic lethality, targeted therapies, cancer research, drug discovery, biotechnology, pharmaceutical, clinical assets, proprietary technology, genetic vulnerabilities.